Athanasios 2007.
Study characteristics | ||
Methods | Study design: parallel‐group, randomized controlled trial Setting/country: Urology Department, ELPIS Hospital, Volos, Greece Dates study conducted: NR |
|
Participants | Inclusion criteria:
Exclusion criteria:
Number of participants randomized: 20 Study length: 12 months Group 1 (duloxetine):
Group 2 (placebo):
|
|
Interventions | Group 1: duloxetine 20 mg daily for 1 week followed by 40 mg daily Group 2: placebo daily |
|
Outcomes | Primary outcome:
Secondary outcome:
Safety outcome:
|
|
Funding sources | NR | |
Declarations of interest | NR | |
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Not described. |
Allocation concealment (selection bias) | Unclear risk | Not described. |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Did not explicitly state that personnel were blinded, only "double blind." |
Blinding of outcome assessment (detection bias) Participant‐reported outcomes | Low risk | Participants appeared to be appropriately blinded. |
Blinding of outcome assessment (detection bias) Investigator‐assessed outcomes | Unclear risk | No explicit description as to how these outcomes were assessed. |
Blinding of outcome assessment (detection bias) IELT | Low risk | Objective measurement that was unlikely to be influenced by blinding. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Unclear how many participants were included in analyses. |
Selective reporting (reporting bias) | Unclear risk | No protocol available. |
Other bias | Low risk | No additional sources of bias identified. |